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ABSTRACT
One of the more recently investigated adverse long-term side effects of gonadotropin-
releasing hormone (GnRH) agonists for prostate cancer (PCa) is cardiovascular disease
(CVD). Studies suggest lower risk of CVD following GnRH antagonists (degarelix) than
GnRH agonists. This protocol describes precise codes used to extract variables from five
European databases for a study that compares risk of CVD following GnRH agonists
and antagonists for PCa. PCa men on primary GnRH agonists or antagonists were
identified from the UK THIN (The Health Improvement Network) database, National
Health Service (NHS) Scotland, Belgian Cancer Registry (BCR), Dutch PHARMO
Database Network and French National Database (SNIIRAM). Cohort entry was
defined as date of treatment initiation. CVD event was defined as any first incident or
fatal CVD after cohort entry. Readcodes in THIN and ICD codes in NHS Scotland,
BCR, PHARMO and SNIIRAM were used to extract variables. Risk of Bias in Non-ran-
domised studies of Interventions (ROBINS-I) tool was used to assess the potential risk
of biases in this study. 51 572 men with a median follow-up time of 2 years started
on GnRH agonists and 2 417 men with a median follow-up time of 1 year started on
GnRH antagonists between 2010 and 2017 in the UK, Scotland, Belgium, the
Netherlands and France. Data from five countries improved the study power and
internal validity required to compare risk of CVD between GnRH agonists and antag-
onists, the latter being a fairly new drug with limited data in individual countries.
INTRODUCT ION
Prostate cancer (PCa) is the most common cancer
among men in Europe, with a further increase in
projected incidence rates [1,2]. By decreasing male
hormone levels, androgen deprivation therapy (ADT)
serves as the mainstream treatment for symptomatic
PCa. More specifically, ADT is commonly used in
doi: 10.1111/fcp.12454
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men with biochemical relapse after radical
prostatectomy (RP), locally advanced PCa and metas-
tasis [3,4].
Several metabolic side effects have been reported for
ADT, including increased body weight, insulin resis-
tance, dyslipidaemia and hyperglycaemia [5–8]. One
of the more recently investigated side effects of ADT is
an increased risk of cardiovascular diseases (CVD),
which is believed to be due to a reduced cardio-pro-
tective effect of testosterone [6,9–12]. In 2010, the
findings from several observational studies [6,9–14]
prompted the Food and Drug Administration (FDA) to
issue a new requirement for manufacturers of certain
types of ADT (gonadotropin-releasing hormone
(GnRH) receptor agonists) to add safety information to
drug labels in order to warn users of the potential
CVD risks involved.
It is therefore of interest to note that degarelix, a
newly introduced GnRH receptor antagonist (2010),
was suggested to be associated with a lower risk of
CVD in PCa men [15,16]. These observations were
also supported by preclinical mouse models showing
less atherosclerosis and characteristics of metabolic
syndrome in mice treated with degarelix as compared
to those with orchiectomy or GnRH agonists [17].
Even though a recent systematic review [18] sug-
gested that GnRH antagonists may be appropriate for
those men with significant CVD risk, existing osteope-
nia, lower urinary tract symptoms and significant
metastatic disease, no results from randomized clinical
trials (RCTs) are available to compare the risk of CVD
between GnRH agonists and antagonists. The PRO-
NOUNCE trial (ClinicalTrials.gov identifier:
NCT02663908), a phase III RCT comparing CVD
safety of leuprolide (GnRH agonist) and degarelix
(GnRH antagonist), is currently recruiting patients
with an anticipated completion date in December
2020 [19]. An observational study, which directly
compared the risk of CVD between GnRH antagonists
and GnRH agonists, detected no difference in risk of
developing stroke and myocardial infarction (MI).
However, overall CVD was not investigated as a speci-
fic outcome [20].
Even though the results of the PRONOUNCE trial
will inform the long-term side effects of GnRH ana-
logues, it is equally important that any results
obtained are applicable to the general PCa population.
Observational studies, when well conducted, provide
similar estimates of side effects to RCTs – which is the
rationale behind phase IV studies [21]. Elderly
participants and those with comorbidities, two
common characteristics of PCa patients receiving ADT,
are often excluded from RCTs [22].
Therefore, we designed a study using real-world evi-
dence from five countries to provide results that are
more applicable to the general PCa population. More-
over, as degarelix was only licensed in 2010, there
was a need to combine data from different countries
(the United Kingdom (UK), Scotland, Belgium, the
Netherlands and France) to obtain a sufficient sample
size. Preliminary results of this study were presented at
the Annual Meeting of the European Association of
Urology, 2018 [23] and the Global Cardio-Oncology
Summit, 2018 [24].
This study describes a methodological protocol which
accounts for heterogeneity in the five databases by
making study variables and analyses as homogenous
as possible. In this protocol, we describe the codes used
to extract study variables from the databases and the
processes and challenges encountered in collecting and
analysing real-world data. When designing the protocol
for this observational study, we followed the design of
a target trial to assess all potential biases by using the
Risk Of Bias In Non-randomised Studies - of Interven-
tions (ROBINS-I) tool [25].
MATER IALS AND METHODS
Study design
To investigate the association between GnRH agonists
or GnRH antagonists and risk of CVD, we designed a
prospective cohort study using databases (described in
the ‘databases’ section below) from the UK, Scotland,
Belgium, the Netherlands and France. The protocol
was designed to obtain country-specific hazard ratios
(stage 1), which were pooled in a meta-analysis
(stage 2).
Target trial
A target trial is a pragmatic trial that emulates a
hypothetical RCT in non-randomized studies of inter-
ventions (NRSIs) and can thus be considered useful
when designing an observational study to assess
effects of different types of drugs. The results of NRSIs
can be evaluated for any risk of bias (RoB) by using
the ROBINS-I tool [25]. The latter is based on seven
specific bias domains that address biases at pre-inter-
vention, during intervention and after intervention
[25]. To ensure a clinically applicable study design for
our real-world study, we used a modified version of
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the ROBINS-I tool to emulate a target trial for risk of
CVD following GnRH agonists or GnRH antagonists in
men with PCa.
Study population
Men with PCa entered the cohort on the date of treatment
(GnRH agonists or GnRH antagonists) initiation. In addi-
tion to exposure variable, cohort entry was also deter-
mined by the presence of advanced or metastatic PCa
where stage of PCa was available (Belgium and the
Netherlands). Once an individual entered the cohort, they
stayed on that treatment regime until time of censoring.
Databases
The health improvement network. The Health Improve-
ment Network (THIN) database is an electronic data-
base that covers more than 11 million patients in the
UK and is representative of 6.2% of the UK population
[26,27]. The database comprises of longitudinal, anon-
ymized data processed and validated by Cegedim
Strategic Data (CSD) Medical Research UK. THIN is
organized into seven different files (Figure 1), which
are extracted from general practices (GP) in the UK
using the VISION [28] system. The data are coded
using standardized codes called the ‘readcodes’ [29] or
‘medcodes’ and ‘drugcodes’. As some individuals may
be present in both THIN and National Health Service
(NHS) Scotland databases, PCa men from Scotland
were excluded from THIN. The study period used for
this project extended from 2010 to 2016.
National health service Scotland. Data were linked from
five databases in Scotland [30]: the Scottish Cancer
Registry, the Scottish National Prescribing Information
System (PIS), the General or Acute Inpatient and Day
Case dataset (SMR01), the Outpatient Attendance data-
set (SMR00) and the National Records of Scotland
Death Records (NRSDR) using the unique identifier
number, Community Health Index Number. The result-
ing dataset captures information on PCa diagnosis and
treatment (from the Scottish Cancer Registry), commu-
nity prescriptions in Scotland (PIS), hospital diagnoses
and operations (SMR01), diagnoses and procedures
from outpatient clinics (SMR00) and the date and
cause of death (NRSDR) [30]. Men diagnosed with PCa
from 2010 to 2015 with follow-up until 2017 were
part of this study.
Belgian cancer registry. All new cancer cases are legally
required to be registered in Belgium in the Belgian
Cancer Registry (BCR) [31]. The database constitutes of
population-based clinical–pathological information on
new cancer diagnoses with almost complete coverage
of the Belgian population since 2004. Administrative
data on reimbursed medical acts and dispensed in- and
outpatient medications are provided to the BCR by the
health insurance companies (HIC), covering a period
from 1 year before until 5 years after the date of can-
cer diagnosis [32]. The HIC data contain information
regarding the date and type of charged diagnostic and
therapeutic procedures, and regarding the date,
amount and dosages of dispensed medications. Follow-
ing specific authorizations, hospital discharge data
(HDD) covering hospitalizations of the patients regis-
tered by BCR from the year prior to the incidence date
onwards are made available using specific codes [33].
These records contain information on hospital admis-
sion and discharge dates, diagnoses and procedures for
each hospitalization. Both HIC and HDD data are deter-
ministically coupled to the BCR database, using the
national social security number as a unique patient
identifier. Cause of death information for all Belgian
inhabitants is provided by the three different Belgian
regions and probabilistically coupled to the BCR data
(coupling percentage 98%). The current project used
data from 2010 to 2013.
PHARMO Database Network. The PHARMO Database
Network is a population-based network of healthcare
databases combining data from both primary and sec-
ondary healthcare settings in the Netherlands [34].
These different data sources, including data from GPs,
in- and outpatient pharmacies, clinical laboratories,
hospitals, the cancer registry, pathology registry and
perinatal registry, are linked on a patient level through
validated algorithms. Detailed information on the
methodology and the validation of the used record link-
age method can be found elsewhere [35]. For this
study, data from the Out-patient Pharmacy Database,
Hospitalisation Database and Cancer Registry were
used. The Out-patient Pharmacy Database includes
detailed information on GP or specialist prescribed
healthcare products dispensed by outpatient pharma-
cies. The dispensing records include information on
type of product, date, strength and dosage regimen,
quantity, route of administration, prescriber specialty
and costs. The Hospitalisation Database comprises of
hospital admissions for more than 24 hours and admis-
sions for less than 24 hours, for which a bed was
required (i.e. inpatient records) from the Dutch Hospital
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Data Foundation. The records include information on
hospital admission and discharge dates, discharge diag-
noses and procedures. The Cancer Registry comprises
information on newly diagnosed cancer patients in the
Netherlands [34]. For the current project, we used data
from 2010 to 2015.
French Health National Database (SNIIRAM). The
French Health National Database based on claims data
called the Systeme National d’Informations Inter-
Regimes de l’Assurance Maladie (SNIIRAM) was used
for this study [36]. SNIIRAM combines reimbursed
claims from insurance plans with the National Hospital
discharge Summaries database system (PMSI). As of
2016, the SNIIRAM includes 98.8% of the French pop-
ulation with follow-up from birth to death [37]. The
database includes information on patient demograph-
ics, hospital and clinical visits, diagnoses of hospitalized
patients (extracted using ICD-10 codes from hospital
visits) and chronic medical conditions. Data between
2010 and 2013 were used for this study.
Study variables
Exposure variable
The exposure variable was defined as prescription or
dispensation of GnRH agonists or GnRH antagonists.
PCa men who were hormone-treatment na€ıve were fol-
lowed from date of first prescription or dispensation
until censoring (defined below).
Outcome variables
The outcome variable was defined as first (incident or
fatal) CVD event (ICD-10: I20-I99, G45 or ICD-9 equiva-
lent) following GnRH agonists or antagonists initiation.
In addition to overall CVD, the following five types of CVD
were considered: ischaemic heart disease (IHD) (ICD-10:
I20-I25), acute myocardial infarction (AMI) (ICD-10:
I21), arrhythmia (ICD-10: I44-I49), heart failure (HF)
(ICD-10: I50, I97.710, I97.790, I11.0) and stroke (ICD-
10: I60-64, G45). The THIN database made use of
already published readcodes [29] similar to the ICD codes.
Censoring
The censoring point was defined as any of the first
occurring among the following: outcome, switch
between GnRH agonists and antagonists and vice
versa, orchiectomy, end of study period or death from
other causes than CVD death during the study period,
whichever came first. Since the six CVD outcomes were
studied separately, only the first event of the interested
outcome at the time of analysis was considered. For
example, when IHD was studied as an outcome, men
Patient
The patient file contains the 
demographic information for 
each patient such as; age, 
sex, registration and 
transferred out dates. 
Additional Health Data 
(AHD)
The AHD file contains 
miscellaneous information 
such as smoking, height, 
weight, immunizations, 
pregnancy and birth and 
death dates.
Therapy
The therapy file contains 
each prescription that the 
patient receives along with 
the date of prescription and 
the formulation, strength, 
quantity and dosing 
instructions for each drug 
being prescribed.
Consult
The consult file contains the 
date, time and duration of a 
particular consultation the 
patient has had.
Staff
The staff file contains the 
gender and role of the staff 
who entered the data into 
the VISION system.
Medical 
The medical file records each 
condition (which is coded by 
‘readcode’) the patient has 
developed with the date of 
diagnosis.
Postcode Variable Indicators 
(PVI)
The PVI file contains 
socioeconomic status, socio-
economic, ethnicity and 
environmental indices based 
on similar areas with a linked 
postcode.
Organization 
of THIN
Figure 1 Organization of data in the
THIN database.
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were censored at first incident or fatal IHD. Any CVD,
AMI, arrhythmia, heart failure and stroke after treat-
ment initiation were overlooked, even if these had
occurred before the IHD event.
Other study variables
Age. Age was considered as a timescale in all analytical
models and was defined at date of GnRH agonists or
antagonists’ initiation. 5 562 men in THIN had miss-
ing date of births which were imputed using multiple
imputation. Age for all men in PHARMO was calcu-
lated using the same random day and month (12th
June) as it only contained the year of birth.
Follow-up time. The median follow-up time and upper
and lower quartiles were calculated for all countries.
Follow-up time began on the date of treatment initia-
tion and ended when they reached any of the censor-
ing criteria discussed above.
Year of PCa diagnosis. Year of PCa diagnosis was
extracted for all countries except for France, where
data for the year of PCa diagnosis was not available.
Stage of PCa. PCa stage was available for Scotland, Bel-
gium and the Netherlands, recorded at the time of PCa
diagnosis. It was defined as locally advanced (T3a/bT4
N0M0) and metastatic (TxNxM1), as most men with
PCa on long-term GnRH analogues are categorized into
these stages. Further PCa stage subgroups were distin-
guished as: TxNxM1, TxN1M0, T3aNxMx, T3bNxMx
and T4NxMx in Belgium.
Total Gleason Score. Total Gleason Score (GS) was avail-
able for Scotland and the Netherlands and was divided
into Gleason 5–6, 7, 8, 9–10 and missing. In the
Netherlands, men with invalid GS (nine patients) were
included in the missing category.
Prostate-specific antigen. Prostate-specific antigen (PSA),
only available for the Netherlands, was categorized
into ≤ 10, 11–20, 21–50 and > 50 ng/mL.
Any prior PCa treatment. Some information on PCa
treatment before GnRH initiation was available for all
five countries. This included men who had undergone
any form of PCa treatment prior to GnRH initiation
such as radical prostatectomy, radical prostatectomy
and adjuvant or salvage radiotherapy (Belgium only),
radiotherapy, chemotherapy (the Netherlands only)
and anti-androgens. In Belgium, radiotherapy was
further split into palliative radiotherapy (1–10
fractions) and long course external beam radiotherapy
(+/- brachytherapy).
Type of ADT. This variable indicated whether ADT
(only in the form of GnRH agonists or antagonists) was
given as primary, adjuvant, neo-adjuvant treatment or
other (Belgium only). No distinction between primary,
neo-adjuvant and adjuvant ADT was made in the UK
due to a lack of accurate data availability on radiother-
apy given to men on ADT. An ADT prescription in Bel-
gium and Scotland was considered neo-adjuvant if it
appeared in the database within 1 month before PCa
incidence and the date of surgery or radiotherapy. An
adjuvant ADT prescription was defined as a prescrip-
tion of GnRH agonists or antagonists within a
6 months’ period following surgery or radiotherapy.
PCa men for whom a treatment (ADT) was found but
had not fulfilled the definitions of primary, adjuvant or
neo-adjuvant ADT treatment (e.g. ADT treatment
started more than 6 months following surgery) were
classed into the ‘other’ category. In the Netherlands,
the cancer registry only had treatment information
given at PCa diagnosis and 6 months after diagnosis
and combination treatment modalities were not derived
for the study. In France, information for radiotherapy
(especially dosages) was not available, and therefore, a
distinction between primary, adjuvant and neo-adju-
vant was not made.
ADT specifics. This variable showed whether ADT was
prescribed in combination with anti-androgens as flare
protection or combined androgen blockade (CAB). Flare
protection was defined as receiving anti-androgens
for ≤ 30 days, whereas CAB was defined as receiving
anti-androgens for more than 30 days.
History of CVD indicator. History of CVD indicator
(HCVDi) was defined as any of the following 12 months
prior to entering the cohort: any CVD event (ICD-10
codes: I20-I99, G45), hypertension (ICD-10 and ATC
codes – Figure 2), dyslipidaemia (ATC codes or drug-
codes – Table III) or diabetes (ATC codes or drugcodes –
Table III). HCVDi was further subcategorized to specifi-
cally indicate history of hypertension, dyslipidaemia or
diabetes 12 months prior to ADT initiation.
Number of previous CVD events. The number of CVD
events prior to entering the cohort was coded as 0, 1,
2 or ≥ 3 CVD events. As data in Belgium were only
ª 2019 The Authors. Fundamental & Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of
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available 1 year before first ADT prescription, previous
CVD events and time of last previous CVD were limited
to the 12 months prior to entering the cohort. The
previous history of CVD was stratified as time of last
previous CVD, defined as no CVD, 0–3 months, 4–
6 months, 7–12 months prior to treatment initiation.
Socio-demographic variables. Body mass index (BMI),
socio-economic status (SES), civil status, smoking status
and ethnicity were extracted in the UK using the read-
codes (Table II for specific codes). BMI was defined as:
underweight at ≤ 18.5 kg/m2, normal at 18.6–24 kg/
m2, overweight at 25–30 kg/m2 and obese at ≥ 30 kg/
m2. Townsend scores [38] were used to extract the SES
of the study population. Townsend scores incorporated
four different variables: unemployment, non-car owner-
ship, non-home ownership and household overcrowd-
ing. The Townsend scores were given as quintiles (i.e.
five groups of equal size ranging from 1 (least deprived)
to 5 (most deprived) [38]). In THIN, civil status was
coded as 12 different codes that were combined to form
three categories: single, married and unknown (Table II).
Smoking status was defined as: current smokers, non-
smokers and past smokers. Ethnicity was defined as men
with an origin of: Caucasian, Black, Asian and other
(readcodes other than these three categories).
Analysis
The analysis was conducted in two stages: stage 1 anal-
ysis was used to assess heterogeneity and prescription
patterns in different countries and stage 2 was a pooled
analysis of PCa cohorts from five countries using meta-
analytical techniques to pool the results. Results of the
meta-analysis will be reported in the main study article.
Stage 1 analysis
Country-specific estimates of hazard ratios were calcu-
lated using Cox proportional hazard models with age
as a timescale. When using age as a timescale, men
entered the cohort at baseline age (left-truncation) and
exited at CVD event age or censoring age. Stage 1
analysis was conducted in four separate steps: (i) age-
adjusted analysis with CVD as outcome, (ii) stratified
analysis based on HCVDi, (iii) multivariable analysis
including HCVDi and (iv) multivariable analysis includ-
ing HCVDi and number of previous CVD events.
Stage 2 analysis
In the second stage, a random-effects meta-analytic
model was performed to compare the pooled log-
transformed country-specific hazard ratios for CVD fol-
lowing GnRH agonists and GnRH antagonists. The
percentage of variation between the databases was
assessed using the I2 statistic. Each country in the
meta-analysis was weighted by the inverse of its vari-
ance (i.e. hazard ratios), and adjustment to the weight
was made based upon the degree of heterogeneity
between the five countries. Heterogeneity in the
assessment of exposure and outcome data was further
evaluated by performing sensitivity analyses. This
included only those countries that had collected data
in a similar way – incident CVD (ICD-9-CM codes)
sourced from hospital discharge date and fatal CVD
(ICD-10 codes) sourced from death certificates in Bel-
gium, ICD-10 codes in Scotland, the Netherlands and
France versus readcodes in the UK. Additional stratifi-
cations by HCVDi as well as age (< 75
and ≥ 75 years) were conducted to assess effect modi-
fication in all countries.
RESULTS
Table I shows the modified ROBINS-I tool used to com-
pare a target trial with this study. This informed the
inclusion/exclusion criteria for the real-world study
population as well as the definitions of all relevant
exposures, outcomes and study variables. The aim of
using the ROBINS-I tool was to understand the types of
biases and challenges involved when dealing with real-
world, heterogeneous data sources. The ROBINS-I tool
highlighted unmeasured confounding, channelling and
misclassification biases.
Table II shows the study period, number of men
with PCa on GnRH agonists and antagonists and
follow-up time (median and quartiles) for the UK,
Scotland, Belgium, the Netherlands and France.
Total median follow-up time for the UK, Scotland,
Belgium, the Netherlands and France was 2 (1.1–
2.8) years for GnRH agonists and 1 (0.7–1.8) year
for GnRH antagonists. High missing numbers for
socio-demographic confounders (BMI, SES, smoking
status and civil status) resulted in an exclusion of
these variables from the analytical models. Table III
shows detailed codes used to extract study variables
from four databases.
An algorithm of ICD and ATC codes (Figure 2) in
Belgium, the Netherlands and France was used to iden-
tify men with hypertension as using ICD codes alone
resulted in a very low number of hypertensive men in
an aged population.
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Figure 2 Algorithm to define hypertension (HTA) used by France and the Netherlands (Panel 1) and modified algorithm used by
Belgium (Panel 2).
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DISCUSS ION
This is the first study to combine real-world data from
five European countries to compare risk of CVD follow-
ing GnRH agonists and GnRH antagonists in men with
PCa. The ROBINS-I tool allowed detailed investigation
of our real-world study design with an emulated RCT
in an attempt to avoid misclassification and unmea-
sured confounding biases. Extraction of baseline and
clinical characteristics defined variables that were to be
included in country-specific analytical models. Homoge-
nous variables in the five countries were then used in
the meta-analytical models.
Real-world data or population-based observational
studies have enabled large-scale studies that allow link-
ages between databases, such as cancer registries, hos-
pital records and epidemiological databases [39].
According to Booth and Tannock, the way forward in
research is to apply RCTs and real-world data in a
complementary manner. Whereas RCTs provide infor-
mation on how to improve efficacy and quality of life
of cancer patients (because they collect lifestyle factors
along with other measurements), real-world data pro-
vide evidence of improvement in outcome (including
safety) at the level of the general population [39].
Therefore, the ROBINS-I tool helped generate a prag-
matic approach to our study design to mimic a target
trial. It specifically allowed a detailed investigation of
trial characteristics, types of biases involved and chal-
lenges encountered when using different databases.
The ROBINS-I tool highlighted some evident and
unavoidable biases associated with observational data
such as uneven randomization distribution and unmea-
sured confounding. Although unmeasured confounding
is often unavoidable in real-world data, VanderWeele
(2017) suggests a ‘straightforward’ E-value calculation
to quantify the minimum strength of association that
an unmeasured confounder would need to have with
treatment and outcome in order to explain the treat-
ment-outcome association [40]. For example, higher E-
values suggest stronger unmeasured confounder associ-
ations to explain the estimated effect.
ROBINS-I tool further highlighted indication bias
also known as channeling bias in pharmacoepidemiol-
ogy. Qayyim Said in Yang and West-Strum (2010)
describes channeling bias as one of the most common
type of bias found in pharmacoepidemiology studies.
Channeling bias arises when the physician treating
patients for a particular disease prescribes certain drugs
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based on patient characteristics such as severity of
disease, age or gender [41]. We accounted for chan-
neling bias by conducting a stratified meta-analysis by
HCVDi. Stratification by HCVDi allowed for estimating
hazard ratios across two strata: those who had a his-
tory of CVD and those who had no history of CVD.
The use of different codes in the five databases
proved difficult to fully homogenize variable definitions.
While readcodes and drugcodes were used to identify
study variables in the UK, ICD and ATC codes were
used in Scotland, Belgium, the Netherlands and France.
Moreover, due to missing observations in socio-demo-
graphic data in the UK, further analyses of lifestyle fac-
tors were not possible.
An algorithm combining ICD and ATC codes (Fig-
ure 2) in Belgium, the Netherlands and France was
used to extract hypertensive men as using ICD codes
alone resulted in a very low number of hypertensive
men in an aged population. We attempted to avoid
classification biases in the five databases by ensuring
that data availability, study variable definitions and
cohort definitions were as uniform as possible
(Table III). As information on compliance to treatment
was not available in our databases, this information
bias will have to be accounted for when interpreting
the results of stage 1 and stage 2 analyses.
The representativeness of the European PCa popula-
tion by incorporating five different databases across
Europe adds strong value to this study. THIN is a pri-
mary healthcare database which represents approxi-
mately 6.2% of the UK population [39]. Whereas THIN
is a primary healthcare database, data in the other four
databases were of other origins. NHS Scotland provides
nationwide medical record linkages between cancer
registry, hospital inpatient and outpatient admission,
dispensed medications and death certificates [30]. BCR
derives information from standard cancer registration,
health insurance companies, hospital discharge data
and cause of death data [31]. The PHARMO Database
Network obtains data from both primary and sec-
ondary healthcare settings which meant that both can-
cer registration and follow-up visits were reliably
available for a patient [35]. The SNIIRAM database
combines a claims database (derived from insurance
funds) with hospital-derived data to form a large data-
base representative of the French population [36]. The
use of primary healthcare, secondary healthcare and
claims databases thus ensured the inclusion of rare,
adverse events that may not have been identified in a
RCT and adds additional strength to the study.Ta
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We used a two-stage approach for the study by
investigating heterogeneity in country-specific analysis.
The country-specific analysis was used to describe pre-
scription patterns and the PCa population in the five
countries. Stage 2 meta-analysis assessed the risk of
outcome due to the two exposures investigated. As
there was no possibility of combining data at the indi-
vidual level (due to legal and ethical restrictions), using
pooled log-transformed hazard ratios of CVD outcomes
were the only way to combine the data. In addition to
creating a homogenous study protocol, we attempted
to further account for heterogeneity using stratified
and sensitivity analyses, as described in the methods
section.
The effect of other treatment modalities in addition
to GnRH agonists or antagonists needs to be considered
when assessing the risk of CVD. This was not consid-
ered in detail for this study because full chemotherapy
and radiotherapy profiles were not available for all
countries. Chemotherapy and radiotherapy are treat-
ment modalities given in a hospital setting, and our
data source was limited in this aspect. As a result, we
were not able to consider other combination treatment
modalities that may have affected CVD outcome. More-
over, data on follow-up treatment modalities affecting
CVD outcome were missing and were therefore a limi-
tation to the study.
A further limitation to the study was that CVD his-
tory was only considered 12 months prior to GnRH
initiation. Although Belgium received information on
CVD history for a maximum of 12 months prior to PCa
diagnosis, the first GnRH prescription was given imme-
diately or a maximum of four months after PCa diag-
nosis (90%). In France, access to CVD history was only
available during the study period (2010–2013) and
accurate information on PCa diagnosis date was not
available. As CVD history was not consistently avail-
able for more than 12 months across the countries, we
defined CVD history to be 12 months prior to first
GnRH prescription. Therefore, all men included in the
study had a minimum of 12 months of CVD history. In
order to keep study definitions homogenous across the
five countries, we assessed history of CVD using the
variable HCVDi.
The variations in prescription patterns of GnRH
antagonists in the five included countries may have
influenced the delivery of GnRH antagonists to a speci-
fic class of PCa men who were predisposed by factors
such as comorbidities and physician preferences. For
instance, a physician may have prescribed GnRH
antagonists to an individual with a history of CVD
based on previous evidence [42]. This means that
GnRH antagonists may have been channeled to this
class of PCa men (channeling bias discussed in Table I).
Channeling may also explain the different proportions
of PCa men on GnRH antagonists across the five coun-
tries. A lower number of men on GnRH antagonists
was observed in the UK compared to the other four
countries, owing to specific guidelines (CG175) [43,44]
only allowing the use of GnRH antagonists in certain
PCa men. Although these specific guidelines deter-
mined the prescription of GnRH antagonists to
advanced hormone-dependent PCa men during the
study period, current UK National Institute of Clinical
Excellence (NICE) guidelines suggest that GnRH antag-
onists should be prescribed to advanced staged PCa
men with a spinal metastasis (NICE TA404) [45].
In Belgium, GnRH antagonists were specified for
advanced stage hormone-dependent PCa; however, no
specifications were made concerning the exact defini-
tion of advanced stage, which left room for interpreta-
tion by the physician [46]. In France, although set
regulations defined classes of patients for whom GnRH
antagonists were prescribed, the decisions were
steered mostly by the physicians who may have
included PCa men with all T-stages with nodal
involvement and metastatic disease [47]. In the
Netherlands, the need for rapid testosterone decline
was achieved by using GnRH antagonists, with switch
to a GnRH agonist after a few months [48]. Potential
differences in prescription and delivery of GnRH
antagonists between UK, Scotland, Belgium, the
Netherlands and France may thus explain the data
heterogeneity between the countries.
CONCLUS ION
When considering the potential heterogeneity intro-
duced by the variation in the means of recording real-
world data, pooling data from five different databases
were found to be a challenge. However, for the first
time we were able to use databases from the UK, Scot-
land, Belgium, the Netherlands and France to include a
heterogeneous PCa population (in contrast to the
selected PCa population in RCTs) across Europe to pro-
vide results that are more applicable to the general
PCa population. The results from this study will help
us understand the variations in risk of long-term CVD
outcomes following GnRH agonists and GnRH antago-
nists in men with PCa.
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